DAT antagonists(Dopamine transporter antagonists), PET imaging(Positron-emission tomography enhancers), SPECT(Single-photon emission-computed tomography enhancers)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication

Parkinson Disease

Inactive Indication

Attention Deficit Disorder With HyperactivityDementiaTremor

Originator Organization

Harvard University

Active Organization

Harvard University

Inactive Organization

Alseres Pharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc.

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC18H21FINO2

InChIKeyGTQLIPQFXVKRKJ-UNSMHXHVSA-N

CAS Registry180468-34-2

Clinical Trials associated with Altropane

NCT05636852

/ TerminatedPhase 2

An Open-label Multicenter Phase 2 Dose-evaluation Study of Altropane (123I) Injection for Striatal Dopamine Transporter Visualization Using SPECT Brain Imaging

Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study determined if a lower dose (5 millicuries) would suffice.

Start Date24 Apr 2023

Sponsor / Collaborator

GE Healthcare Holdings, Inc.

[+1]

NCT01950468

/ WithdrawnPhase 3

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

This is a phase 3, open-label, multiple-center, randomized cross-over study to assess the safety and efficacy of [123I]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.

Start Date01 Apr 2017

Sponsor / Collaborator

Navidea Biopharmaceuticals, Inc.

NCT01950455

/ TerminatedPhase 3

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

This is a phase 3, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of [123I]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.

Start Date01 Nov 2013

Sponsor / Collaborator

Navidea Biopharmaceuticals, Inc.

100 Clinical Results associated with Altropane

100 Translational Medicine associated with Altropane

100 Patents (Medical) associated with Altropane

154

Literatures (Medical) associated with Altropane

01 Dec 2025·JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Elucidating allosteric signal disruption in PBP2a: impact of N146K/E150K mutations on ceftaroline resistance in methicillin-resistant Staphylococcus aureus

Article

Author: Luo, Qing ; Guo, Jingjing ; Tong, Henry H Y ; Jiao, Fangfang ; Xu, Ran ; Li, Xinkang

Ceftaroline (CFT) effectively combats methicillin-resistant Staphylococcus aureus (MRSA) by binding to the allosteric site on penicillin-binding protein 2a (PBP2a) and activating allosteric signals that remotely open the active pocket. However, the widespread clinical use of CFT has led to specific mutations, such as N146K/E150K, at the PBP2a allosteric site, which confers resistance to CFT in MRSA by disrupting the transmission of allosteric signals. Herein, computational simulations were employed to elucidate how the mutations disrupt the transmission of allosteric signals, thereby enhancing the resistance of MRSA to CFT. Specifically, the mutations alter the salt bridge network and electrostatic environment, resulting in a dynamic setting and decreased binding affinity of CFT within the allosteric pocket. Additionally, dynamical network analysis and the identification of allosteric pathways revealed that the reduced binding affinity diminishes the propagation of allosteric signals to the active site. Further evaluations demonstrated that this diminished signaling reduces the openness of the active pocket in the mutant systems, with "gatekeeper" residues and functional loops remaining partially closed. Redocking experiments confirmed that mutations lead to decreased docking scores and unfavorable docking poses for CFT within the active pocket. These findings highlight the complex interactions between structural changes induced by mutations and antibiotic resistance, providing crucial insights for developing new therapeutic strategies against MRSA resistance.

01 Oct 2025·BEHAVIOUR RESEARCH AND THERAPY

Mechanisms of change in cognitive functional therapy: A longitudinal mediation analysis of the RESTORE clinical trial for disabling chronic low back pain

Article

Author: Caneiro, J P ; Attwell, Stephanie ; Hartvigsen, Jan ; McGregor, Alison ; Schütze, Robert ; Kent, Peter ; O'Sullivan, Peter ; O'Sullivan, Kieran ; Campbell, Amity ; Smith, Anne ; Hancock, Mark ; Liew, Bernard

Chronic low back pain (CLBP) is an urgent global health priority given its high prevalence and impact as the leading cause of disability. While several efficacious treatments exist, most have modest effects. Improving outcomes requires a better understanding of treatment mechanisms to enable optimisation. This study explored the mechanisms of cognitive functional therapy (CFT), a biopsychosocial intervention with large, durable effects for adults with disabling CLBP. A longitudinal mediation analysis was performed on data from the RESTORE multisite clinical trial comparing CFT (n = 327) to usual care (n = 165). Mediators (self-efficacy, fear, catastrophising, and pain intensity) were specified based on behavioural theories underlying CFT and previous research. The joint mediation of treatment effects on disability (Roland Morris Disability Questionnaire) and pain intensity (numerical rating scale), were examined using a counterfactual framework for mediation analysis. As hypothesised, earlier changes in self-efficacy, fear, catastrophising, and pain intensity mediated improvements in disability at the end of treatment and at 12-month follow-up, explaining up to 61 % of the effect. Similarly, self-efficacy, fear, and catastrophising mediated the effect of CFT on pain intensity, explaining up to 62 % of the effect. Results are consistent with previous CLBP mediation research highlighting self-efficacy, fear, and catastrophising as likely common mechanisms among effective biopsychosocial treatments. CFT demonstrates large, durable, and clinically important effects on these mechanisms. Findings shed light for clinicians and researchers on how CFT works, although the role of other mechanisms such as movement changes requires further exploration, along with research analysing how different treatment components activate these mechanisms.

01 Jan 2026·JOURNAL OF VASCULAR SURGERY

Association between serum testosterone and related hormones and risk of symptomatic abdominal aortic aneurysm in male participants from the UK Biobank

Article

Author: Pu, Hongji ; Qiu, Peng ; Tran, Cammie ; Zheng, Jiazhen ; Sun, Pin ; Ye, Kaichuang ; Wu, Zhaoyu ; Li, Fengshi ; Yang, Xinrui ; Liu, Guang ; Liu, Yijun ; Guo, Hongbin ; Lu, Xinwu ; Zhou, Zhen ; Wang, Ruihua ; Xu, Zhijue

BACKGROUND:

Ruptured abdominal aortic aneurysm (AAA) is associated with high mortality risk. Few studies found a relationship between testosterone levels and AAA development, but were limited by small event numbers and single-center design.

OBJECTIVE:

To assess the associations of serum testosterone and sex hormone-binding globulin (SHBG) levels with symptomatic AAA risk in male participants from the UK Biobank.

METHODS:

Study exposures included baseline serum total testosterone (TT), free testosterone (cFT and FTZ), bioavailable testosterone, and SHBG. Multivariable Cox proportional hazards regression models were used for outcome analyses. The joint association of male hormones and AAA polygenic risk score (PRS) was further investigated with AAA risk.

RESULTS:

This study followed 190,627 males over 15 years, with 1903 symptomatic AAA cases identified. Compared with those in higher quartiles, individuals in the lowest quartile of TT, FTZ, cFT and BioT had a 19% (95% confidence interval [CI], 1.07-1.33), 16% (95% CI, 1.05-1.28), 8% (95% CI, 0.98-1.19), and 13% (95% CI, 1.03-1.25) higher risk of AAA, respectively. For SHBG, individuals in the highest quartile had a 20% (95% CI, 1.07-1.34) greater risk of AAA compared with those in lower quartiles. Stratified analysis by AAA, PRS found that individuals with higher PRS and either lower testosterone levels or higher SHBG levels, had a greater risk of developing AAA.

CONCLUSIONS:

This large population-based cohort study found that higher PRS and either lower testosterone or highest SHBG were associated with a greater risk of symptomatic AAA among male individuals. Owing to the observational nature of this study, further research is warranted to establish whether or not a causal relationship exists between lower testosterone and the development or growth of an AAA, and whether testosterone treatment might decrease the risk of AAA.

News (Medical) associated with Altropane

27 Mar 2006

·www.biospace.com

Boston Life Sciences To Present At The CIBC World Markets Annual Biotechnology And Specialty Pharmaceuticals Conference

HOPKINTON, Mass., March 28 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. today announced that Kenneth L. Rice, Jr., Chief Financial Officer of Boston Life Sciences, Inc., will be presenting a Company update at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference on Tuesday, April 4 at 9:00am EST. The conference is being held April 4 - 5, 2006 at the Millennium Broadway in New York City. The Boston Life Sciences presentation will be available by webcast. Access to the webcast will be available for 90 days following the presentation within the Investor Relations section of the Boston Life Sciences website at . About Boston Life Sciences, Inc. Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and a Phase II clinical trial for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of stroke, a DAT blocker for the treatment of Parkinson's disease and a second generation technetium-based molecular imaging agent for PS and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital of Boston. ALTROPANE is a registered trademark of Boston Life Sciences, Inc. The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future, including the Company's development efforts regarding the Company's ALTROPANE program and the Company's pre-clinical candidates. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on form 10-Q for the quarter ended September 30, 2005, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Boston Life Sciences, Inc. is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. Contact: Sharon Correia -- 508-497-2360 ext 224 Boston Life Sciences, Inc. scorreia@bostonlifesciences.com Boston Life Sciences, Inc. CONTACT: Sharon Correia of Boston Life Sciences, Inc., +1-508-497-2360ext. 224, scorreia@bostonlifesciences.com Web site:

Collaborate

100 Deals associated with Altropane

External Link

KEGG	Wiki	ATC	Drug Bank
-	Altropane	-	DB04947

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Phase 3	United States	Navidea Biopharmaceuticals, Inc.	01 Nov 2013
Parkinsonian Disorders	Phase 3	United States	Alseres Pharmaceuticals, Inc.	01 Jul 2010
Tremor	Phase 3	United States	Alseres Pharmaceuticals, Inc.	01 Jul 2010
Dementia	Phase 2	United States	Alseres Pharmaceuticals, Inc.	19 Oct 2013
Attention Deficit Disorder With Hyperactivity	Phase 2	United States	Alseres Pharmaceuticals, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05636852 (CTgov)	Phase 2	Parkinson Disease	15	Altropane (123I)	nknjuiyrcz = vvcrgkdghf uepptgzbqc (aksorsdilk, qsovpqlggx - vpoutddmzq) View more	-	15 Jul 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis